Argenx Eyes Larger Patient Pool Following Expanded FDA Nod For Lead Drug For Neuromuscular Disease

Argenx SE – ADR (NASDAQ:ARGX) shares are up during Monday's session as the company celebrates a recent FDA approval for its drug, VYVGART, which adult patients with generalized myasthenia gravis can use.